← All trials
NCT06282692
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 19, 2023
- Primary completion
- May 19, 2024
- Completion date
- Jul 19, 2024
- First posted
- Feb 28, 2024
- Last posted
- Feb 28, 2024
- Enrollment
- 400
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Dr. Soetomo General HospitalLead sponsor
- Dr. Soetomo General HospitalOfficial
- Airlangga UniversityCollaborator
- Biotis Pharmaceuticals, IndonesiaCollaborator
- Government of IndonesiaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.